These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 14502663)
1. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Fitzmaurice PS; Ang L; Guttman M; Rajput AH; Furukawa Y; Kish SJ Mov Disord; 2003 Sep; 18(9):969-76. PubMed ID: 14502663 [TBL] [Abstract][Full Text] [Related]
2. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]
3. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242 [TBL] [Abstract][Full Text] [Related]
4. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Bukhatwa S; Zeng BY; Rose S; Jenner P Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003 [TBL] [Abstract][Full Text] [Related]
6. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386 [TBL] [Abstract][Full Text] [Related]
7. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875 [TBL] [Abstract][Full Text] [Related]
8. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Juh R; Kim J; Moon D; Choe B; Suh T Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329 [TBL] [Abstract][Full Text] [Related]
9. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321 [TBL] [Abstract][Full Text] [Related]
10. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590 [TBL] [Abstract][Full Text] [Related]
11. Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease. Rascol O; Sabatini U; Fabre N; Senard JM; Simonetta-Moreau M; Montastruc JL; Clanet M; Rascol A Mov Disord; 1995 Mar; 10(2):163-70. PubMed ID: 7753058 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Holmberg B; Johnels B; Blennow K; Rosengren L Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213 [TBL] [Abstract][Full Text] [Related]
13. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803 [TBL] [Abstract][Full Text] [Related]
14. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119 [TBL] [Abstract][Full Text] [Related]
15. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Tong J; Fitzmaurice PS; Ang LC; Furukawa Y; Guttman M; Kish SJ Ann Neurol; 2004 Jan; 55(1):125-9. PubMed ID: 14705122 [TBL] [Abstract][Full Text] [Related]
16. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846 [TBL] [Abstract][Full Text] [Related]
17. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Perry TL; Yong VW Neurosci Lett; 1986 Jun; 67(3):269-74. PubMed ID: 3737015 [TBL] [Abstract][Full Text] [Related]
18. New and reliable MRI diagnosis for progressive supranuclear palsy. Oba H; Yagishita A; Terada H; Barkovich AJ; Kutomi K; Yamauchi T; Furui S; Shimizu T; Uchigata M; Matsumura K; Sonoo M; Sakai M; Takada K; Harasawa A; Takeshita K; Kohtake H; Tanaka H; Suzuki S Neurology; 2005 Jun; 64(12):2050-5. PubMed ID: 15985570 [TBL] [Abstract][Full Text] [Related]
19. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ashour R; Jankovic J Mov Disord; 2006 Nov; 21(11):1856-63. PubMed ID: 16941460 [TBL] [Abstract][Full Text] [Related]
20. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation. Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]